512 related articles for article (PubMed ID: 28947345)
1. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
[TBL] [Abstract][Full Text] [Related]
2. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B
Lancet Infect Dis; 2020 May; 20(5):585-597. PubMed ID: 32032566
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
[TBL] [Abstract][Full Text] [Related]
4. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
Younis S; Faber BW; Kocken CHM; Remarque EJ
BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques.
Kusi KA; Remarque EJ; Riasat V; Walraven V; Thomas AW; Faber BW; Kocken CH
Malar J; 2011 Jul; 10():182. PubMed ID: 21726452
[TBL] [Abstract][Full Text] [Related]
7. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.
Sagara I; Ellis RD; Dicko A; Niambele MB; Kamate B; Guindo O; Sissoko MS; Fay MP; Guindo MA; Kante O; Saye R; Miura K; Long C; Mullen GE; Pierce M; Martin LB; Rausch K; Dolo A; Diallo DA; Miller LH; Doumbo OK
Vaccine; 2009 Dec; 27(52):7292-8. PubMed ID: 19874925
[TBL] [Abstract][Full Text] [Related]
8. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits.
Remarque EJ; Faber BW; Kocken CH; Thomas AW
Infect Immun; 2008 Jun; 76(6):2660-70. PubMed ID: 18378635
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
Mullen GE; Ellis RD; Miura K; Malkin E; Nolan C; Hay M; Fay MP; Saul A; Zhu D; Rausch K; Moretz S; Zhou H; Long CA; Miller LH; Treanor J
PLoS One; 2008 Aug; 3(8):e2940. PubMed ID: 18698359
[TBL] [Abstract][Full Text] [Related]
10. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.
Pierce MA; Ellis RD; Martin LB; Malkin E; Tierney E; Miura K; Fay MP; Marjason J; Elliott SL; Mullen GED; Rausch K; Zhu D; Long CA; Miller LH
Vaccine; 2010 Mar; 28(10):2236-2242. PubMed ID: 20051276
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.
Thera MA; Doumbo OK; Coulibaly D; Laurens MB; Kone AK; Guindo AB; Traore K; Sissoko M; Diallo DA; Diarra I; Kouriba B; Daou M; Dolo A; Baby M; Sissoko MS; Sagara I; Niangaly A; Traore I; Olotu A; Godeaux O; Leach A; Dubois MC; Ballou WR; Cohen J; Thompson D; Dube T; Soisson L; Diggs CL; Takala SL; Lyke KE; House B; Lanar DE; Dutta S; Heppner DG; Plowe CV
PLoS One; 2010 Feb; 5(2):e9041. PubMed ID: 20140214
[TBL] [Abstract][Full Text] [Related]
13. The Candidate Blood-stage Malaria Vaccine P27A Induces a Robust Humoral Response in a Fast Track to the Field Phase 1 Trial in Exposed and Nonexposed Volunteers.
Steiner-Monard V; Kamaka K; Karoui O; Roethlisberger S; Audran R; Daubenberger C; Fayet-Mello A; Erdmann-Voisin A; Felger I; Geiger K; Govender L; Houard S; Huber E; Mayor C; Mkindi C; Portevin D; Rusch S; Schmidlin S; Tiendrebeogo RW; Theisen M; Thierry AC; Vallotton L; Corradin G; Leroy O; Abdulla S; Shekalaghe S; Genton B; Spertini F; Jongo SA
Clin Infect Dis; 2019 Jan; 68(3):466-474. PubMed ID: 29945169
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02
Berry AA; Gottlieb ER; Kouriba B; Diarra I; Thera MA; Dutta S; Coulibaly D; Ouattara A; Niangaly A; Kone AK; Traore K; Tolo Y; Mishcherkin V; Soisson L; Diggs CL; Blackwelder WC; Laurens MB; Sztein MB; Doumbo OK; Plowe CV; Lyke KE
Malar J; 2019 Jan; 18(1):13. PubMed ID: 30658710
[TBL] [Abstract][Full Text] [Related]
15. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults.
Remarque EJ; Roestenberg M; Younis S; Walraven V; van der Werff N; Faber BW; Leroy O; Sauerwein R; Kocken CH; Thomas AW
PLoS One; 2012; 7(6):e38898. PubMed ID: 22768052
[TBL] [Abstract][Full Text] [Related]
16. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
[TBL] [Abstract][Full Text] [Related]
17. Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response.
Kusi KA; Faber BW; Riasat V; Thomas AW; Kocken CH; Remarque EJ
PLoS One; 2010 Nov; 5(11):e15391. PubMed ID: 21082025
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.
Malkin E; Hu J; Li Z; Chen Z; Bi X; Reed Z; Dubovsky F; Liu J; Wang Q; Pan X; Chen T; Giersing B; Xu Y; Kang X; Gu J; Shen Q; Tucker K; Tierney E; Pan W; Long C; Cao Z
Vaccine; 2008 Dec; 26(52):6864-73. PubMed ID: 18930094
[TBL] [Abstract][Full Text] [Related]
19. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide.
Mullen GE; Giersing BK; Ajose-Popoola O; Davis HL; Kothe C; Zhou H; Aebig J; Dobrescu G; Saul A; Long CA
Vaccine; 2006 Mar; 24(14):2497-505. PubMed ID: 16434128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
